Product Images Xalkori

This seems to be a table showing survival probabilities in a clinical trial comparing XALKORI to chemotherapy. The Hazard Ratio is 0.45 which indicates that the group treated with XALKORI had a better survival outcome. The median survival time for the XALKORI group was 10.9 months versus 7.0 months for the chemotherapy group. The table also shows the number of subjects at risk for each group.*

This is a chart with data comparing the median progression-free survival of 173 individuals administered XALKORI versus 174 individuals receiving chemotherapy. The chart shows that the median progression-free survival for XALKORI was 7.7 months whereas chemotherapy had a median of 3.0 months. The data is presented in a hazard ratio format with a 95% Cl of 0.37-0.64 and p<0.001. Further, the graph shows progression-free survival probability over time for both treatments. The XALKORI group showed a survival probability of approximately 80%, and the chemotherapy group showed a survival probability of approximately 60% over the same duration.*

Pfizer is a pharmaceutical company whose products are distributed by Pfizer Labs, a division of Pfizer Inc. The company is based in New York, NY 10017.*

The text provides information about a company called Pfizer Labs which is a division of Pfizer Inc. It also indicates that the company is based in New York with a zip code of 10017. The text does not provide any other details.*

Store crizotinib capsules at room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F) in tight containers as per the USP guidelines. The medication should always be dispensed enclosed per the guide to each patient. Each capsule of XALKORI contains 250 mg of crizotinib. The dosage and use of the medication should be as prescribed in the accompanying prescribing information. Pfizer Labs, a division of Pfizer Inc, distributes the medication, and it is manufactured in Ireland. The capsules should be swallowed whole.*